This is a preview of subscription content, log in via an institution to check access.
Reference
Decision Resources. Through 2021, Small-Molecule Angiogenesis Inhibitors Will Dominate the Renal Cell Carcinoma Treatment Landscape and the Market Share for this Drug Class Will Peak in 2017 at Nearly 85 Percent. Media Release : 26 Nov 2012. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
Small-molecule angiogenesis inhibitors will lead RCC therapy. PharmacoEconomics & Outcomes News 668, 11 (2012). https://doi.org/10.1007/s40274-012-0038-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-012-0038-2